Email this article 
ANDROGEN DEPRIVATION THERAPY WITH LUTEINIZING HORMONE-RELEASING HORMONE ANTAGONISTS FOR PROSTATE CANCER: BEST DISEASE CONTROL WITH A LOWER RISK OF SIDE EFFECTS. RESULTS OF ANALYSIS OF 6 COMPARATIVE RANDOMIZED PHASE III TRIALS OF DEGARELIX AND LUTEINIZIN
- Authors: Markova A.S.1, Matveev V.B.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
- Issue: Vol 10, No 1 (2014)
- Pages: 76-81
- Section: REVIEW
- Published: 30.03.2014
- URL: https://oncourology.abvpress.ru/oncur/article/view/25
- DOI: https://doi.org/10.17650/1726-9776-2014-10-1-76-81
- ID: 25
Cite item
Full Text
Abstract
Androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) antagonists versus therapy with agonists of this hormone ensures a better disease control due to the rapider and persistent suppression of testosterone levels without a flare phenomenon and requires no preventive use of antiandrogens. The third-generation LHRH antagonist degarelix shows a good tolerability and causes no systemic al-lergic reactions inherent in the earlier known drugs of this group. As indicated, the use of degarelix was characterized by the longer response of prostate-specific antigen (PSA) with a lower risk of adverse reactions, namely, serious cardiovascular and osseous complications, urinary tract infections (UTI). Thus, in males with a history of cardiovascular diseases, the risk of serious cardiovascular events or death decreased by 56% just within the first year of degarelix therapy. The findings allow degarelix to be regarded as the drug of choice for first-line hormone therapy in patients with advanced PC, particularly in males with cardiovascular disease or a high risk for UTI and osseous complications.
About the authors
A. S. Markova
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: mark-an1@yandex.ru
Russian Federation
V. B. Matveev
N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, Moscow
Email: mark-an1@yandex.ru
Russian Federation
References
Supplementary files
